Temporary contraindication to chemotherapy due to toxicity: blinatumomab's effectiveness in paediatric patients with B‐acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

Temporary contraindication to chemotherapy due to toxicity: blinatumomab's effectiveness in paediatric patients with B‐acute lymphoblastic leukaemia

Published:2023-03-27 Issue:4 Volume:201 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Collignon C.¹^ORCID,Domenech C.²,Ducassou S.³^ORCID,Pluchart C.⁴^ORCID,Bruno B.⁵,Pasquet M.⁶,Simon P.⁷,Petit A.⁸^ORCID,Rialland‐Battisti F.⁹,Brethon B.¹⁰

Affiliation:

1. Pediatric Intensive Care Unit APHP University Hospital Necker‐Enfants Malades Paris France

2. Institute of Pediatric Hematology and Oncology Hospices Civils de Lyon, Université Lyon 1 Lyon France

3. Pediatrics Oncology Department Children's Hospital of Bordeaux University Hospital Bordeaux France

4. Pediatric Hematology‐Oncology Unit CHU Reims Reims France

5. Pediatric Hematology Unit CHU Lille Lille France

6. Pediatric Hematology‐Oncology Unit CHU Toulouse Toulouse France

7. Pediatric Hematology‐Oncology Unit CHU Besançon Besançon France

8. Sorbonne Université, Hôpital Armand Trousseau, AP‐HP Paris France

9. Pediatric Hematology‐Oncology Unit CHU Nantes Nantes France

10. Hematology and Immunology Pediatric Unit Robert Debré Hospital Paris France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18759

Reference13 articles.

1. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration

2. Crisis management in the treatment of childhood acute lymphoblastic leukemia: putting right what can go wrong (emergency complications of disease and treatment)

3. Next-Generation Evaluation and Treatment of Pediatric Acute Lymphoblastic Leukemia

4. Haute Autorité de Santé ‐ BLINCYTO Comission de la Transparence‐Avis CT17807.2019[cited Jan 2020]. Available from:https://www.has‐sante.fr/jcms/p_3146311/fr/blincyto‐blinatumomab

5. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blinatumomab;Reactions Weekly;2023-12-09

2. Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL;Journal of Clinical Oncology;2023-11-15